# Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

> **NCT03093831** · PHASE2 · TERMINATED · sponsor: **National Cancer Centre, Singapore** · enrollment: 5 (actual)

## Conditions studied

- Lymphoma, B-Cell, Marginal Zone

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03093831
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-08
- **Primary completion:** 2020-07-17
- **Final completion:** 2020-07-17
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study did not meet the objectives and terminated early on 17 Jul 2020 due to poor recruitment
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093831, "Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03093831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*